#GLP-1

Researchers traced semaglutide’s activity inside appetite-regulating neurons and found a molecular mechanism that may explain both strong responses and eventual plateaus.

New tracking from EPIC Research suggests rapid growth in GLP-1 prescribing has coincided with a small but sustained drop in obesity rates across a large medical-records dataset.

A nationwide self-controlled study in Denmark found people with asthma who started GLP-1 drugs saw fewer exacerbations and less reliever inhaler use over the following year.

A phase 3b trial published in Nature Medicine found that daily oral orforglipron helped people maintain more of their prior weight loss after tirzepatide or semaglutide than placebo over 52 weeks.

European regulators have cleared Fractyl Health to begin what the source describes as the first clinical test of a GLP-1 gene therapy. The decision signals how aggressively drug developers are pursuing alternatives to长期?

Researchers at Helmholtz Munich have built a hybrid obesity therapy that uses GLP-1 and GIP signaling to deliver a second metabolic drug into target cells, producing stronger weight-loss and glucose effects in mice.

A new Medicare pilot would let some beneficiaries access GLP-1 weight-loss medicines for about $50 a month starting July 1, but the short-term design, eligibility rules, and prior authorization requirements leave major a

Researchers analyzing electronic health records from nearly 20 million patients report rapid growth in GLP-1 prescribing, even as many people with severe obesity still receive no treatment and bariatric surgery use slips

A review of 11 major cardiovascular trials found GLP-1 receptor agonists were linked to fewer heart attacks, strokes, and cardiovascular deaths over nearly three years of follow-up, extending the case for the drugs wellb

Researchers at Helmholtz Munich report a new treatment concept that combines GLP-1 and GIP signaling in a single hybrid molecule, with the goal of addressing obesity and type 2 diabetes together.

CMS has indefinitely delayed a Medicare pilot focused on obesity medication coverage after insurance plans signaled they were not ready to participate.

Novo Nordisk is navigating two departures at once, including the retirement of GLP-1 pioneer Lotte Bjerre Knudsen and the loss of an obesity leader to Boehringer Ingelheim.

A study announced by the 23andMe Research Institute identified genetic predictors tied to both GLP-1 weight-loss efficacy and side effects, highlighting a possible path toward more personalized obesity treatment.

Two phase 3 EVOKE(+) trials found that semaglutide did not slow clinical progression in Alzheimer’s disease, despite earlier signals that GLP-1 drugs might help.

Structure Therapeutics reports encouraging Phase 2 results for its oral GLP-1 receptor agonist, advancing a pill-form alternative to injectable weight-loss and diabetes drugs.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.

Eli Lilly launches a program to make it easier for employers to add GLP-1 weight loss and diabetes drugs to their health plans, addressing a major coverage gap.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.

With one in eight American adults now taking GLP-1 medications like Ozempic and Wegovy, researchers at Georgia State University have uncovered why patients regain weight after stopping treatment — and a potential combination therapy that could solve the problem by targeting the brain's stress response system.